SCHEMBL22976532

SCHEMBL22976532

COc1ncc(C(=O)O)c(N2CC[C@](C)(NC(=O)OC(C)(C)C)C2)c1-c1cc(F)cc(F)c1

nearest known ligand 0.37

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ RET P07949 15/20 0.37
▸ HDAC1 Q13547 1/20 0.32
▸ HDAC2 Q92769 1/20 0.32
▸ PIK3R1 P27986 1/20 0.32
▸ PIK3CA P42336 1/20 0.32
▸ ABCB1 P08183 1/20 0.31
▸ JAK2 O60674 1/20 0.31
▸ NTRK1 P04629 1/20 0.31
▸ RAF1 P04049 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29720113 1.00 RET (0.37) RETHDAC1HDAC2PIK3R1PIK3CA
SCHEMBL22976535 1.00 RET (0.37) RETHDAC1HDAC2PIK3R1PIK3CA
SCHEMBL29653559 0.93 RET (0.37) RETHDAC1HDAC2PIK3R1PIK3CA
SCHEMBL31243145 0.93 RET (0.37) RETHDAC1HDAC2PIK3R1PIK3CA
SCHEMBL22976758 0.90 RET (0.37) RETHDAC1HDAC2PIK3R1PIK3CA
SCHEMBL22976755 0.90 RET (0.37) RETHDAC1HDAC2PIK3R1PIK3CA
SCHEMBL29720051 0.90 RET (0.37) RETHDAC1HDAC2PIK3R1PIK3CA
SCHEMBL22976375 0.87 RET (0.36) RETHDAC1HDAC2PIK3R1PIK3CA
SCHEMBL22976526 0.87 RET (0.42) RET
SCHEMBL22976372 0.87 RET (0.36) RETHDAC1HDAC2PIK3R1PIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12600709-B2 Nonpeptide somatostatin type 5 receptor agonists and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2026-04-14 — — US disclosed
US-20250136573-A1 NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF Crinetics Pharmaceuticals, Inc. 2025-05-01 — — US disclosed
US-11479540-B2 Nonpeptide somatostatin type 5 receptor agonists and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2022-10-25 — — US disclosed
EP-4013748-A1 NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF Crinetics Pharmaceuticals, Inc. (US) 2022-06-22 — — EP disclosed
CN-114585614-A Non-peptide somatostatin type 5 receptor agonists and uses thereof 克林提克斯医药股份有限公司 2022-06-03 — — CN disclosed
US-20220144802-A1 NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF Crinetics Pharmaceuticals, Inc. 2022-05-12 — — US disclosed
WO-2021030262-A1 NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF Crinetics Pharmaceuticals, Inc. (US) 2021-02-18 — — WO disclosed
US-20210047287-A1 NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF Crinetics Pharmaceuticals, Inc. 2021-02-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220144802-A1 NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF SSTR5, SSTR4, SSTR3 RET 478/4885HDAC1 3032/4885HDAC2 2912/4885
US-11479540-B2 Nonpeptide somatostatin type 5 receptor agonists and uses thereof SSTR5, SSTR4, SSTR3 RET 478/4885HDAC1 3032/4885HDAC2 2912/4885
US-20250136573-A1 NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF SSTR5, SSTR4, SSTR3 RET 478/4885HDAC1 3032/4885HDAC2 2912/4885
US-20210047287-A1 NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF SSTR5, SSTR4, SSTR3 RET 478/4885HDAC1 3032/4885HDAC2 2912/4885
US-12600709-B2 Nonpeptide somatostatin type 5 receptor agonists and uses thereof SSTR5, SSTR4, GLP1R RET 398/4885HDAC1 1992/4885HDAC2 1723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback